Market Size
Global Hyperuricemia Market reached US$ 1.89 billion in 2025 and is expected to reach US$ 4.01 billion by 2033, growing with a CAGR of 5.4% during the forecast period 2026-2033.
When the bloodstream contains an excessive amount of uric acid, hyperuricemia occurs. Although it doesn't have any symptoms, it can induce diseases like gout or kidney stones. Purine, a substance found in a variety of meals, is broken down by the body to create uric acid as a byproduct.
The amount of uric acid in the blood can be decreased by consuming fewer purine-rich meals and beverages. The kidneys can once again filter uric acid out more efficiently because to this lowering. Compared to men, women have a substantially lower prevalence of hyperuricemia, with 1-2% of those under the age of 50 and about 3% of those over the age of 50.
Moreover, gout has been linked to cancer, psoriasis, atrial fibrillation, thromboembolism, COPD, and thromboembolism, according to recent studies. Due to its serious complications and significant impact on health-related quality of life, hyperuricemia and gout have come to prominence as a public health concern. The prevalence of hyperuricemia has risen significantly as a result of rapid economic development and lifestyle changes.
Market Scope
| Metrics | Details |
| CAGR | 5.4% |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Age Group, Drug Type , Route of Administration, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | North America |
| Largest Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report Request for Sample
Market Dynamics
Increasing the Product Approvals and Clinical trails
Novel objectives and paths for intervention have been found as a result of ongoing study into the underlying causes of hyperuricemia and the molecular mechanisms of related disorders like gout. This makes it possible for newly created medications and treatments to become successful.
The US Food and Drug Administration (USFDA) gave final approval to Zydus Lifesciences company to market Febuxostat tablets, 40 mg and 80 mg. The reference listed medicine Uloric pills are equivalent to the approved Febuxostat tablets, 40 mg and 80 mg. The purpose of febuxostat tablets is to reduce hyperuricemia (high levels of uric acid in the blood) in gout patients who have either undergone unsuccessful allopurinol treatment or are ineligible for allopurinol therapy.
Topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States has been distributed by Urica Therapeutics, Inc., a Fortress Biotech, Inc. subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. With no severe adverse effects reported at any dose level, dotinurad (a new urate transporter) was demonstrated to be safe and well tolerated. Thus, the expansion of clinical trials and product approvals fuels the market.
The Increasing Geriatric Population
The function of the kidneys can decrease as ageing population. Filtering and excreting uric acid from the body is a critical function of the kidneys. Reduced kidney function can result in less uric acid being excreted from the body, which causes uric acid levels in the blood to rise and is a sign of hyperuricemia.
Aged persons may encounter changes in their dietary preferences and levels of physical activity. With aging, unhealthy eating patterns like drinking excessive alcohol or purine-rich meals become more prevalent. These elements may be responsible for higher uric acid levels in aged people.
In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population. By thus increasing the geriatric population will drive the market growth.
Lack of Awareness about Hyperuricemia Diagnosis
The risks to health linked to hyperuricemia may not be fully recognized by many people, including medical experts. This lack of knowledge may result in a delayed diagnosis and poor care. Furthermore, hyperuricemia is rarely detected during standard medical exams, especially in people without a known history of gout or other related disorders. Patients might not be aware of their increased uric acid levels without routine testing. Some medical professionals might not give individuals who don't have certain symptoms or risk factors for hyperuricemia testing priority. Missed chances for early detection and education may come from this. Thus, the previous factors hinder market expansion.
Segment Analysis
The global hyperuricemia market is segmented based on type, age group, drug type, route of administration, distribution channel and region.
Xanthine Oxidase Inhibitors are Needed for Treatment
A class of drugs called Xanthine Oxidase Inhibitors (XO Inhibitors) is used to treat hyperuricemia, a disorder indicated by high amounts of uric acid in the blood. Hyperuricemia can cause uric acid crystals to develop, which can subsequently build up in joints and cause painful inflammation that could eventually result in diseases like gout.
Targeting the xanthine oxidase enzyme, which is essential for the synthesis of uric acid, is how XO inhibitors function. The enzyme xanthine oxidase is in charge of turning the uric acid precursors hypoxanthine and xanthine into uric acid. The body produces less uric acid when this enzyme is inhibited, which lowers the total levels of uric acid in the circulation. XO Inhibitors work by blocking this enzyme. It has been demonstrated that XO inhibitors are efficient at reducing uric acid levels and treating the signs and symptoms of hyperuricemia and gout. They are well-researched drugs with a successful track record in therapeutic use. Thus, these mentioned factors aid in accelerating segment expansion.
Geographical Share
Prevalence of the Diseases in the North American Region
Due to factors such as an aging population, an increase in obesity cases, technological improvements, and company strategies, North America is anticipated to hold the majority of the market over the forecast period. For instance, insulin resistance, a disorder in which the body's cells cannot respond to insulin, a hormone that aids in blood sugar regulation, is frequently linked to obesity.
Increased blood insulin levels brought on by insulin resistance may impair the kidneys' capacity to eliminate uric acid. Uric acid levels may increase as a result. As a result, the market may grow faster in the area due to the rise in obesity. For instance, according to healthline media stated that, over 42% of American adults are thought to be obese, while 30.7% are thought to be overweight. Overweight or obese conditions affect more than two thirds of American people overall.
Ages 40 to 59 are when adults are most likely to be obese. In actuality, obesity affects more than 44% of adults in this age range. In the meantime, 41.5% of individuals over the age of 60 and 39.8% of adults between the ages of 20 and 39 are obese. Thus, all of those variables accelerate market expansion in the region.
Key Developments
- December 2025: XORTX Therapeutics Inc. announced new genome-wide research linking more than 410 genetic factors with gout and hyperuricemia pathways. The company highlighted advancements in xanthine oxidase (XO) inhibition research and confirmed progress toward NDA preparation for its oxypurinol-based gout and hyperuricemia therapy platform.
- September 2025: Shanton Pharma received U.S. FDA Fast Track designation for SAP-001 for treatment-resistant hyperuricemia in adult gout patients. The designation followed positive Phase IIb clinical data demonstrating a novel kidney-transporter targeting mechanism aimed at improving serum uric acid reduction in refractory patients.
- July 2025: Eisai Co., Ltd. launched URECE® (dotinurad) in China for gout patients with hyperuricemia following regulatory approval. The URAT1 inhibitor demonstrated superior serum uric acid reduction over febuxostat in a Phase III study, marking a significant technological advancement in selective uric acid reabsorption inhibition therapies.
Competitive Landscape
The major global players in the market include Arthrosi Therapeutics, Inc, Dr.Reddy's, Urica Therapeutics, Inc, Zydus Lifesciences, Takeda Pharmaceutical Company Limited, Novartis AG, Hikma Pharmaceuticals Plc, Mylan N.V., AstraZeneca Plc, Sun Pharmaceutical Industries Ltd and among others.
Why Purchase the Report?
- To visualize the global hyperuricemia market segmentation based on type, age group, drug type, route of adminstration, distribution channel and region,as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of hyperuricemia market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global Hyperuricemia market report would provide approximately 61tables, 58figures and 186 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
